Osterweis Capital Management Inc. Buys New Shares in Boston Scientific Corporation $BSX

Osterweis Capital Management Inc. acquired a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, Holdings Channel reports. The firm acquired 708,949 shares of the medical equipment provider’s stock, valued at approximately $30,258,000. Boston Scientific accounts for about 1.4% of Osterweis Capital Management Inc.’s investment portfolio, making the stock its 27th biggest position.

A number of other large investors have also added to or reduced their stakes in BSX. Kelleher Financial Advisors bought a new position in shares of Boston Scientific in the second quarter valued at about $25,000. FWL Investment Management LLC bought a new position in shares of Boston Scientific during the second quarter worth approximately $26,000. Swiss RE Ltd. acquired a new position in Boston Scientific in the 4th quarter valued at $26,000. Garton & Associates Financial Advisors LLC acquired a new position in Boston Scientific in the fourth quarter valued at about $26,000. Finally, Clal Insurance Enterprises Holdings Ltd acquired a new position in shares of Boston Scientific in the 1st quarter valued at approximately $28,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

BSX stock opened at $48.98 on Tuesday. The firm has a 50 day moving average of $46.38 and a 200-day moving average of $57.32. The firm has a market capitalization of $70.99 billion, a P/E ratio of 19.83, a price-to-earnings-growth ratio of 1.10 and a beta of 0.56. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter last year, the business posted $0.75 earnings per share. The firm’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has initiated a stock repurchase program on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its shares are undervalued.

Insider Activity

In related news, Director Edward J. Ludwig acquired 5,000 shares of the company’s stock in a transaction dated Friday, July 31st. The stock was bought at an average cost of $45.48 per share, with a total value of $227,400.00. Following the acquisition, the director owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael F. Mahoney acquired 186,240 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have purchased 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Citigroup dropped their price objective on Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. The Goldman Sachs Group set a $71.00 price target on shares of Boston Scientific in a research note on Thursday, May 28th. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. Mizuho dropped their target price on shares of Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. Finally, Weiss Ratings cut shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, July 7th. Twenty-four analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.